Skip to content

Strategic Partners

Greg Buczyński

Project Management & Governance

Twenty-five years of governance and global program leadership behind the companies I build.

Greg Buczyński
Greg BuczyńskiStrategic Partner
“Greg is the reason I trust the foundation under everything we build.”
Tim Kinzie

Why Greg Matters

Greg is a strategic partner and a friend, and one of the first people I build with. He spent more than 25 years leading global programs in one of the most regulated industries there is, where every decision is documented, every number is audited, and nothing ships until it is right.

He brings that same standard to the companies I build. Greg runs the operating and governance side: compliance, licensing, insurance, filings, and the reviews that keep a growing group of companies in good standing as they change. It is the work nobody sees when it is done right, and it is what makes scale survivable. Because Greg holds that line, I can keep building.

Highlights

The Record

25+ Years leading global programs
$200M Global oncology program directed
FDA + EMA Regulatory submissions supported
3 Countries joined in one tech transfer

Contribution

What Greg Brings

01

Governance That Holds

Compliance, licensing, filings and the reviews that keep every company in good standing as it grows and changes.

02

Programs, Delivered

A career of driving complex programs from concept to global launch, across teams, sites and countries.

03

Numbers You Can Trust

Decades of data integrity and executive reporting: what leadership sees is what is true.

Ventures

Ventures Associated With

Private Portfolio CompaniesA private group of founder-led companies I build with.

Career

About Greg

  • Ph.D., Chemistry
  • PMP Certified
  • cGMP / cGLP
  • FDA + EMA

Greg Buczyński is a PMP-certified program and project management leader with more than 25 years in highly regulated biotherapeutics. A Ph.D. chemist by training, he rose from the lab at Grifols Therapeutics (formerly Bayer) to Deputy Director of its Project Management Office, where for over a decade he drove programs from concept through global launch, supported FDA and EMA submissions, and led technology transfers from North Carolina to new facilities in Ireland and Canada.

Most recently, as a Program Manager at Fujifilm Diosynth Biotechnologies, he directed a $200 million global program to manufacture potential oncology biotherapeutics. He holds a Ph.D. and a B.S. in Chemistry from the University of South Florida.

Published with Greg’s approval.